As MannKind Corporation (NASDAQ: MNKD) prepares to release its earnings report on Monday, August 11, both investors and short sellers wait in suspense. The company recently signed an agreement to secure its supply for synthesizing the "Super Rapid Acting Insulin" Afrezza from a French biopharmaceutical firm, Amphastar Pharmaceuticals (NASDAQ: AMPH).  Afrezza offers unparalleled convenience over the traditional drugs used for injection of mealtime insulin, Novolog and Humalog. The "Super Rapid Acting Insulin Afrezza" exhibits the kinetics similar to a healthy pancreas, and is delivered through a small whistle-like device called the Dreamboat, offering patients convenience and improving compliance, thereby  reducing dreaded diabetic complications annually costing $245 billion.

Source: MannKind

Read More at: Retail Investor 360